SEC Form 4 · accession 0001055726-17-000016
INOVIO PHARMACEUTICALS, INC. · INO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
George Bickerstaff
Director
Period of report
Mar 21, 2017
Accepted (ET)
Mar 23, 2017 · 4:16 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001055726
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock OptionF1 | $5.86 | Mar 21, 2017 | A | 20,000 | A | Mar 21, 2017 | Mar 21, 2027 | Common Stock | 20,000 | 20,000 | D |
| Restricted Stock UnitF2 | — | Mar 21, 2017 | A | 12,270 | A | — | — | Common Stock | 12,270 | 12,270 | D |
Explanation of responses
- F1The vesting schedule for the 20,000 options is as follows: 5,000 shares vested on March 21, 2017; 5,000 shares will vest on March 21, 2018; 5,000 shares will vest on March 21, 2019; 5,000 shares will vest on March 21, 2020.
- F2Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 12,270 restricted stock units is as follows: 4,090 shares will vest on March 21, 2018; 4,090 shares will vest on March 21, 2019; 4,090 shares will vest on March 21, 2020. Vested units of restricted stock can be settled in shares of common stock, cash or a combination of both.